UPM Pharmaceuticals: Topnotch Drug Development Quality and Speed Thanks to Its Dedicated Facility

Sept. 13, 2010 - PRLog -- For over a decade, pharmaceutical firms needing help with drug development have turned to UPM Pharmaceuticals. The company offers clients a broad range of services relating to pharmaceutical development. The selection of services it offers includes formulation evaluation, regulatory support, and small-scale clinical and commercial drug manufacturing.

In order for it to be able to guarantee the quality of the medicines it produces, UPM Pharmaceuticals knows that it is of prime importance to be able to oversee and manage every aspect of the pharmaceutical development process, from development of the final formulation to the mass production of the actual medicines. In support of this, the company maintains its own large multi-purpose drug development and production facility in Baltimore.

UPM Pharmaceuticals’ special facility incorporates state-of-the-art equipment that gives the company unparalleled control over the drug-development process. UPM has the ability to manage every step of the pharmaceutical development process for its clients. Research and development, formulation analysis, cGMP drug manufacturing, and packaging can be done in-house thanks to this facility. In addition, the company’s use of key technology and conformance with established international quality standards enables it to produce medicines rapidly, while still being able to maintain consistently high quality levels.

To find out more about UPM Pharmaceuticals and its drug development expertise, please visit http://www.upm-inc.com or call 410-843-3738

# # #

About UPM Pharmaceuticals:

UPM Pharmaceuticals has been meeting the drug development needs of the most exacting pharmaceutical clients for more than ten years. The company maintains a cutting-edge facility in Baltimore that enables it to meet clients’ needs rapidly without compromising product quality. Visit http://www.upm-inc.com or call 410-843-3738 to learn more.